Latest Axitinib Stories

2014-05-30 08:25:14

Retrospective Analysis Demonstrates Survival Benefits for Patients with Stable and Progressive Disease after HD IL-2 in the Modern Era Suggesting Appropriate Drug Sequencing May Improve Outcomes CHICAGO, May 30, 2014 /PRNewswire/ -- Prometheus Laboratories Inc. announced today that analysis of data from the PROCLAIM(SM) national patient registry retrospective cohort shows improved overall survival in metastatic RCC patients treated with high-dose Proleukin(®) (aldesleukin) in the...

2014-01-24 08:24:33

HAIFA, Israel, Jan. 24, 2014 /PRNewswire/ -- Novocure announced today that the first patient has enrolled in the EF-20 Study, an open label, pilot clinical trial of NovoTTF Therapy plus gemcitabine as first-line therapy for patients with locally advanced and metastatic pancreatic adenocarcinoma. NovoTTF Therapy is an anti-mitotic treatment delivered continuously with a wearable, home-use medical device. "The EF-20 study builds on extensive preclinical research demonstrating the...

2013-09-20 23:04:05

The celebrity-hosted program will feature SFL Pharmaceuticals in an upcoming Medical Minutes segment. Coral Springs, FL (PRWEB) September 20, 2013 The producers of Health Briefs TV are pleased to announce that SFJ Pharmaceuticals will be featured in an upcoming segment on "Innovative Drug Development and Clinical Research Driving Improved Patient Care" as part of the show's Medical Minutes series. Their value of pharmaceuticals is especially evident in the field of...

2012-04-03 09:00:10

The combination of the novel drug TH-302 with the standard drug gemcitabine has shown early signs of delaying the worsening of cancer in patients with advanced pancreatic cancer, a Mayo Clinic-led study has found. This was evaluated using a measure termed progression-free survival (PFS). According to the results of a multi-center Phase II clinical trial, patients receiving the combination of gemcitabine and TH-302 demonstrated a progression-free survival of 5.6 months compared to 3.6 months...

2012-04-03 08:44:26

Additional compounds may help first-line drug kill cancer cells, according to new research by scientists at Fox Chase Cancer Center Scientists at Fox Chase Cancer Center are developing a new way to treat pancreatic cancer by boosting the effects of gemcitabine (Gemzar)–the chemotherapy drug that is considered standard therapy for the disease. Although gemcitabine is the first line of defense against pancreatic cancer, many cells find ways to evade the treatment. The new research,...

2012-01-30 18:10:00

BioPlus Specialty Pharmacy selected as one of the limited number of specialty pharmacies with access to this advanced renal cell carcinoma second line therapy. Altamonte Springs, Florida (PRWEB) January 30, 2012 BioPlus Specialty Pharmacy (BioPlus), one of the nation´s leading specialty pharmacies, has launched axitinib (brand name: Inlyta, from Pfizer), a new cancer drug just approved by the FDA. BioPlus is pleased to be one of the small number of specialty pharmacies with access to...

Word of the Day
  • Like a worm in form or movement; vermiform; tortuous or sinuous; also, writhing or wriggling.
  • Like the track or trace of a worm; appearing as if worm-eaten; vermiculate.
  • Marked with fine, close-set, wavy or tortuous lines of color; vermiculated.
  • A form of rusticated masonry which is so wrought as to appear thickly indented with worm-tracks.
This word ultimately comes from the Latin 'vermis,' worm.